Published in Future Med Chem on November 01, 2009
Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem (2010) 1.60
Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. Antimicrob Agents Chemother (2011) 0.95
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother (2013) 0.79
Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection. ACS Med Chem Lett (2010) 0.78
Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site. Biochemistry (2013) 0.77
Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol (2013) 0.77
Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor. Proc Natl Acad Sci U S A (2017) 0.75
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem (2010) 2.87
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem (2010) 1.60
Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol (2012) 1.39
Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res (2011) 1.35
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry (2003) 1.32
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother (2004) 1.27
Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938. Antimicrob Agents Chemother (2012) 1.12
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut (2013) 0.98
Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase. Antivir Chem Chemother (2003) 0.98
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology (2012) 0.97
Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. Antimicrob Agents Chemother (2011) 0.95
A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. Biochem Biophys Res Commun (2013) 0.95
Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res (2013) 0.92
2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg Med Chem Lett (2010) 0.91
Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol (2011) 0.87
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol (2013) 0.87
Interaction of 2'-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma. Antivir Chem Chemother (2007) 0.86
Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Res (2002) 0.86
Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther (2008) 0.85
Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Antivir Ther (2010) 0.83
Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. Hepatol Res (2014) 0.82
Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. Hepatol Res (2013) 0.80
Use of 2'-spirocyclic ethers in HCV nucleoside design. J Med Chem (2013) 0.80
Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. J Gastroenterol Hepatol (2015) 0.80
Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother (2013) 0.79
[Significant regression of a cavernous hepatic hemangioma to a sclerosed hemangioma over 12 years: a case study]. Nihon Shokakibyo Gakkai Zasshi (2011) 0.79
Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives. J Med Chem (2014) 0.78
A 2'-deoxy-2'-fluoro-2'-C-methyl uridine cyclopentyl carbocyclic analog and its phosphoramidate prodrug as inhibitors of HCV NS5B polymerase. Nucleosides Nucleotides Nucleic Acids (2012) 0.78
Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate. Bioorg Med Chem Lett (2012) 0.78
Inhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimetics. Bioorg Med Chem Lett (2012) 0.77
Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. Hepatol Res (2011) 0.77
[A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer]. Gan To Kagaku Ryoho (2010) 0.77
[A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma]. Gan To Kagaku Ryoho (2009) 0.76
β-D-2'-α-F-2'-β-C-Methyl-6-O-substituted 3',5'-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: a structure-activity relationship study. Bioorg Med Chem Lett (2012) 0.76
Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine. Antimicrob Agents Chemother (2005) 0.75
Synthesis and anti-HCV activity of 3',4'-oxetane nucleosides. Bioorg Med Chem Lett (2010) 0.75
Synthesis and biological activity of 5',9-anhydro-3-purine-isonucleosides as potential anti-hepatitis C virus agents. Nucleosides Nucleotides Nucleic Acids (2007) 0.75
[Yakon tea induced hepatitis in a patient with alcoholic liver cirrhosis]. Nihon Shokakibyo Gakkai Zasshi (2009) 0.75
[A case of clonorchiasis complicated with the expansion of liver cyst]. Nihon Shokakibyo Gakkai Zasshi (2013) 0.75